Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06489249 · ClinicalTrials.gov registry record · Early Phase 1
Role of Inflammation in Vascular Phenotype Associated With E-cigarette Use
A Early Phase 1 study of Inflammation and Endothelial Dysfunction, sponsored by University of Iowa.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 24
- Enrollment target
- 2
- Study locations
NCT06489249 is a Early Phase 1 study of Inflammation and Endothelial Dysfunction that is actively recruiting participants, run by University of Iowa. The registered enrollment target is 24 participants, below the 288-participant average among 132 other Inflammation trials with a reported enrollment target (92% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT06489249, a Early Phase 1 study of Inflammation and Endothelial Dysfunction, is actively recruiting participants, sponsored by University of Iowa.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 24 participants
- Enrollment target
- 2
- Study locations
Study Summary
The use of electronic nicotine delivery systems, or e-cigarettes - colloquially referred to as "vaping" - in the United States has increased exponentially since their introduction to the US market in 2007. Prevalence of ever and current e-cigarette use is highest among teenagers and young adults with 16-28% of this population having reported vaping. While the majority of e-cigarette users are current tobacco smokers, 32.5% of current e-cigarette users are never- or former-smokers, representing a growing population of young adults who exclusively vape. While e-cigarettes have been marketed as a safer alternative to tobacco cigarettes, clinical studies examining these claims are limited. Cardiovascular disease (CVD) is the primary cause of premature death among tobacco cigarette smokers and reductions in vascular endothelial function, a significant predictor of future CVD, are detectible in otherwise healthy young adults who smoke. Despite the explosion in e-cigarette use among young adults, the health effects - especially the effects on mechanisms of vascular function - of these devices remain relatively unexplored. The purpose of this study is to directly asses the mechanistic role of inflammation in this dysfunction.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Salsalate 750 MG Oral Tablet [DISALCID]
Study Locations (2)
Iowa
- Iowa Bioscience Innovation Facility - Iowa City
- University of Iowa - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2024-08-15 |
| Est. Completion | 2026-10 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06489249
The ClinicalTrials.gov registry entry for NCT06489249 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 288-participant average among 132 other Inflammation trials with a reported enrollment target (92% lower). The listed sponsor is University of Iowa, which has 228 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Inflammation appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06489249 reports 2 study locations spanning 1 distinct geographic area - top geographies include Iowa.
Frequently Asked Questions
What is clinical trial NCT06489249 about?
NCT06489249 is a clinical study titled "Role of Inflammation in Vascular Phenotype Associated With E-cigarette Use". The use of electronic nicotine delivery systems, or e-cigarettes - colloquially referred to as "vaping" - in the United States has increased exponentially since their introduction to the US market in 2007. Prevalence of ever and current e-cigarette use is highest among teenagers and young adults wit...
What is the current status of trial NCT06489249?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 24 participants. The study started on 2024-08-15. Estimated completion is 2026-10.
What conditions does trial NCT06489249 study?
This clinical trial studies the following conditions: Inflammation, Endothelial Dysfunction, Electronic Cigarette Use.
What interventions are being tested in trial NCT06489249?
The interventions under investigation include: Placebo (DRUG), Salsalate 750 MG Oral Tablet [DISALCID] (DRUG).
Who is sponsoring clinical trial NCT06489249?
This trial is sponsored by University of Iowa, which has 228 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06489249 being conducted?
This trial has 2 study locations across Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Inflammation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sleep and Inflammatory Resolution Pathway
ACTIVE NOT RECRUITING · Early Phase 1
-
Induction of Gut Permeability by an Oral Vaccine
ACTIVE NOT RECRUITING · Early Phase 1
-
Effect of High-Legume Diet on Colorectal Cancer Risk
COMPLETED · Early Phase 1
-
Ketone Ester And Salt (KEAS) in Older Adults
RECRUITING · NA
-
Reducing Suicide Risk Among Aging Caregivers of Persons With AD/ADRD
RECRUITING · NA
-
Reducing Frailty for Older Cancer Survivors Using Supplements II
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.